For research use only. Not for therapeutic Use.
Dasantafil (Cat No.: I006387) is a synthetic compound primarily investigated for its potential as a treatment in cardiovascular diseases. It functions as a selective inhibitor of the angiotensin II receptor type 1 (AT1), which plays a critical role in regulating blood pressure and fluid balance. By blocking this receptor, Dasantafil can help reduce hypertension and protect against heart failure. Research is ongoing to evaluate its efficacy and safety, making it a promising candidate for managing conditions related to the renin-angiotensin-aldosterone system.
| CAS Number | 569351-91-3 |
| Synonyms | 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1R,2R)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione |
| Molecular Formula | C22H28BrN5O5 |
| Purity | ≥95% |
| IUPAC Name | 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1R,2R)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione |
| InChI | InChI=1S/C22H28BrN5O5/c1-3-26-20(31)18-19(27(9-10-29)22(26)32)25-21(24-15-5-4-6-16(15)30)28(18)12-13-7-8-17(33-2)14(23)11-13/h7-8,11,15-16,29-30H,3-6,9-10,12H2,1-2H3,(H,24,25)/t15-,16-/m1/s1 |
| InChIKey | RCJYGWGQCPDYSL-HZPDHXFCSA-N |
| SMILES | CCN1C(=O)C2=C(N=C(N2CC3=CC(=C(C=C3)OC)Br)NC4CCCC4O)N(C1=O)CCO |
| Reference | [1]. Galo M, et al. Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. Pulm Circ. 2020 Jul-Sep; 10(3): 2045894020948780. |
